We found that tipifarnib inhibits CXCL12 expression in pancreatic stellate cells and reduces tumor growth of KRAS WT PDAC in PDX models, suggesting that tipifarnib may benefit a subset of PDAC patients. This evidence concerns the gene KRAS and neoplasm.